Source:http://linkedlifedata.com/resource/pubmed/id/11516566
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2001-8-22
|
pubmed:abstractText |
Bradykinin is one of the key molecules involved in the disruption of the blood-brain barrier and blood-spinal cord barrier occurring after spinal cord injury (SCI). Previously we have shown a biphasic opening of the blood-spinal cord barrier as well as increased transport of tumor necrosis factor-alpha (TNFalpha) after SCI by compression of the lumbar spinal cord in mice. To evaluate the role of bradykinin in the two phases of blood-spinal cord barrier disruption, we pretreated mice with a potent bradykinin antagonist, the decapeptide B9430, before SCI. Our results show that B9430 decreased the general blood-spinal cord barrier disruption occurring immediately after SCI but failed to affect the delayed opening of the blood-spinal cord barrier observed 72 h after SCI. By contrast, the entry of TNFalpha after SCI was not affected by B9430 treatment. We conclude that bradykinin is involved in the early phase of blood-spinal cord barrier disruption, with B9430 non-selectively blocking this early disruption without affecting the selective transport system for TNFalpha. This indicates the therapeutic potential of bradykinin antagonists in ameliorating tissue damage induced by SCI.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/B 9430,
http://linkedlifedata.com/resource/pubmed/chemical/Bradykinin,
http://linkedlifedata.com/resource/pubmed/chemical/Iodine Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Technetium Tc 99m Aggregated Albumin,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0304-3940
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
6
|
pubmed:volume |
307
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
25-8
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:11516566-Animals,
pubmed-meshheading:11516566-Blood-Brain Barrier,
pubmed-meshheading:11516566-Bradykinin,
pubmed-meshheading:11516566-Cell Membrane Permeability,
pubmed-meshheading:11516566-Iodine Radioisotopes,
pubmed-meshheading:11516566-Male,
pubmed-meshheading:11516566-Mice,
pubmed-meshheading:11516566-Mice, Inbred ICR,
pubmed-meshheading:11516566-Spinal Cord,
pubmed-meshheading:11516566-Spinal Cord Injuries,
pubmed-meshheading:11516566-Technetium Tc 99m Aggregated Albumin,
pubmed-meshheading:11516566-Time Factors,
pubmed-meshheading:11516566-Tumor Necrosis Factor-alpha
|
pubmed:year |
2001
|
pubmed:articleTitle |
Bradykinin antagonist decreases early disruption of the blood-spinal cord barrier after spinal cord injury in mice.
|
pubmed:affiliation |
VA Medical Center and Department of Medicine, Tulane University School of Medicine, 1601 Perdido Street, New Orleans, LA 70112, USA. wpan@tulane.edu
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|